
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
In this short film directed by Caskey, Ben has to make a difficult choice: continue to live with hallucinations, or confront reality, by taking medications that will destroy his imaginary world.
A




